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their antimicrobial and antiviral activities. Representative derivatives of the newly synthesized com-
pounds were tested. Ampicillin, clotimazole and the antiviral antibiotic aphidicolin were used as
positive controls. Compound 18 proved to be the most active member of this series as antimicrobial
against Staphylococcus aureus and Candida albicans and as antiviral with IC50 value of 0.21 mg/ml
and CD50 value of 0.02 mg/ml while compound 19 proved to be the most active member of this ser-
ies as antiviral with IC50 value of 0.21 mg/ml and CD50 value of 0.01 mg/ml.
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Search for new antiviral agents is becoming the major interest
in many academic and industrial research laboratories all over
the world. This is due to the urge to discover new antiviral
agents with more speciﬁcity and less toxicity, in addition to
the various types of new viruses that are discovered nowadays
and which is becoming a great challenge for the scientists. The
adamantane nucleus was found to be important constituent in6 1 2914843.
(G.S. Hassan).
ity. All rights reserved. Peer-
d University.
lseviermany antiviral drugs. This is because of its various mecha-
nisms of action towards viruses. The incorporation of an ada-
mantyl moiety into a pharmacologically-active molecule – in
many cases – resulted in improving the therapeutic proﬁle of
the parent drug (Spano et al., 1970). Since the discovery of
amantadine (I) (Stetter, 1962; Gerzon et al., 1963; Lee et al.,
1966; Kirschbaum, 1983) as the ﬁrst antiviral therapy for sys-
temic use, several hundreds or even thousands of 1-adamantyl
and 2-adamantyl derivatives were synthesized and tested for
various biological activities. Rimantadine (II) and its biologi-
cally-active metabolites (III–V) (Manchand et al., 1990) were
tested and some of them were proved to have antiviral activity.
Antimicrobial and antiviral properties were also observed as a
major biological effect of several fused adamantyl heterocycles
systems such as oxadiazole (El-Emam et al., 2004), isoxazole
(Makarova et al., 2002) and thiadiazole (Kritsanida et al.,
2002). Moreover, several thiazolidinone derivatives were re-
ported to display antimicrobial activity (Mehta et al., 2008;
Subudhi et al., 2007; Sattigeri et al., 2005; Hirapara et al.,
124 G.S. Hassan et al.2003). Also thiazolidinone nucleus represented the major nu-
cleus in several derivatives possessing hypnotic (Ergenc et al.,
1999), anticonvulsant (Verma and Saraf, 2008), analgesic (Tar-
analli et al., 2007), antitumor (Guezel and Salman, 2009) and
anthelmintic (Khan and Yusuf, 2009) activities. Furthermore,
some oxadiazoline derivatives were proved to have anti-HIV
activity (Chimirri et al., 1994). In addition, some other
oxadiazoline derivatives showed other pharmacological activi-
ties such as anti-inﬂammatory (Tiperciuc et al., 1999), antitu-
mor (Abadi et al., 2003), and antibacterial activity (Li et al.,
2008). Accordingly, in the present investigation, some new het-
erocyclic derivatives carrying 1-adamantyl moiety were pre-
pared as hybrid compounds which might possess antiviral
and/or antimicrobial activity, and these were tested for such
activities.
2. Experimental
2.1. General
Melting points (C) were determined on Fischer–Johon melt-
ing point apparatus and are uncorrected. Microanalyses were
performed in the microanalytical unit, Faculty of Sciences,
Cairo University and the found values were within ±0.4%
of the theoretical values. Reaction times were determined using
TLC silica gel plates 60 F254‘‘E. Merck’’ the spots were visual-
ized by UV (366, 254 nm). 1H NMR spectra were recorded on
a Bruker AC 250 FT NMR spectrometer at 250 MHz using
CDCl3 or DMSO-d6 as solvent and TMS as internal standard.
The chemical shifts were expressed in d ppm. Splitting patterns
were designated as follows: s, singlet; brs, broad singlet; d,
doublet and m, multiplet. Mass spectra were recorded on a
Shimadzu GC MS 1000 EX at 70 eV. The in vitro antimicro-
bial testing was performed at Department of Microbiology,
Faculty of Pharmacy, Mansoura University, Egypt. The agar
disc-diffusion method and a panel of standard strains (Staph-
ylococcus aureus IFO 3060, Escherichia coli IFO 3301, and
Candida albicans IFO 0583) were employed. Compounds 2
(Kolocouris et al., 2007), 3 (Bormasheva et al., 2008) and 4–
17 (Henry and Colwell Jr., 1973) were prepared according to
the literature procedures.
2.2. Chemistry
(±) 3-(1-Adamantylcarbonylamino)-2-aryl-4-thiazolidinones
(18–27): A mixture of the appropriate arylideneamino deriva-
tive 4–17 (0.004 mol) and mercaptoacetic acid (1.0 ml) in ben-
zene or xylene (10 ml) was heated under reﬂux for 4 h. The
solvent was then evaporated under reduced pressure and the
resulted residue was washed several times with 10% sodium
bicarbonate solution and ﬁnally with water, dried and crystal-
lized from pet. ether to yield the products 18–27 in 80–90%
yields. 18: 1.62–1.99 (m, 15H, Adamantyl-H), 3.66–3.81 (d,
2H, CH2, J= 16), 5.91 (s, 1H, CH), 7.08–7.39 (m, 5H, Ar-
H, NH). 19: m/z (% Rel. Int.); 392 (0.06, M+ +1), 391
(0.16, M+). 1.60–2.0 (m, 15H, Adamantyl-H), 3.67–3.81 (d,
2H, CH2, J= 15.9), 5.89 (s, 1H, CH), 7.15 (s, 1H, NH),
7.33–7.37 (d, 4H, Ar-H, J= 8.6). 20: 1.63–1.99 (m, 15H, Ada-
mantyl-H), 3.70–3.80 (d, 2H, CH2, J= 15.9), 6.39 (s, 1H,
CH), 7.30–7.51 (m, 5H, Ar-H, NH). 21: m/z (% Rel. Int.);
437 (0.25, M+ +2), 435 (0.26, M+). 1.63–2.02(m, 15H,Adamantyl-H), 3.68–3.81 (d, 2H, CH2, J= 15.9), 5.88 (s,
1H, CH), 7.56 (s, 1H, NH), 7.29–7.52 (d, 4H, Ar-H, J= 7.9).
22: m/z (% Rel. Int.); 370 (0.03, M+). 23: 1.62–1.98 (m, 15H,
Adamantyl-H), 2.98 (s, 6H, N(CH3)2), 3.64–3.79 (dd, 2H,
CH2, J= 15.9), 5.83 (s, 1H, CH), 6.70–7.25 (m, 5H, Ar-H,
NH). 24: 1.63–1.99 (m, 15H, Adamantyl-H), 3.75–3.80 (d,
2H, CH2, J= 15.3), 6.59 (d, 1H, J= 1.83, CH), 7.17 (s, 1H,
NH), 7.24–7.36 (m, 3H, Ar-H). 25: 1.62–1.99 (m, 15H, Ada-
mantyl-H), 3.66–3.81 (d, 2H, CH2, J= 15.8), 3.90 (s, 6H,
OCH3), 5.87 (s, 1H, CH), 6.83–6.96 (m, 3H, Ar-H), 7.13 (s,
1H, NH). 26: 1.63–1.99 (m, 15H, Adamantyl-H), 3.68 (m, 2H,
CH2), 6.62 (s, 1H, CH), 7.03–7.39 (m, 4H, NH, Ar-H). 27:
1.56–1.90 (m, 15H, Adamantyl-H), 3.69–3.82 (m, 2H, CH2),
5.71 (s, 1H, CH), 7.08–7.38 (m, 3H, Ar-H), 9.68 (s, 1H, NH).
(±) 2-(1-Adamantyl)-4-acetyl-5-aryl-1,3,4-oxadiazolines
(28–33): A mixture of the appropriate arylideneamino deriva-
tive 4–17 (0.004 mol) and acetic anhydride (10 ml) was heated
under reﬂux for 2 h. The excess acetic anhydride was then
evaporated under reduced pressure and ice-water (50 ml) was
added to the resulted oily or sticky residue and refrigerated
for 2 h. The separated solid was ﬁltered, washed with water,
dried and crystallized from pet. ether to yield the products
28–33 in 35–50% yields. 28: 1.58–2.13 (m, 15H, Adamantyl-
H), 2.23 (s, 3H, COCH3), 6.84 (s, 1H, CH), 7.06–7.39 (m,
4H, Ar-H). 29: 1.69–2.13 (m, 15H, Adamantyl-H), 2.39 (s,
3H, COCH3), 3.87 (s, 3H, OCH3), 7.69 (s, 1H, CH), 6.99–
7.97 (m, 4H, Ar-H). 30: 1.59–2.07 (m, 15H, Adamantyl-H),
2.29 (s, 3H, COCH3), 7.59 (s, 1H, CH), 7.41–8.02 (m, 4H,
Ar-H). 31: 1.84–2.16 (m, 18H, Adamantyl-H, COCH3), 7.26
(s, 1H, CH), 7.72–8.84 (m, 4H, Ar-H). 32: 1.60–2.08 (m,
15H, Adamantyl-H), 2.25 (s, 3H, COCH3), 6.94 (s, 1H, CH),
7.60–8.24 (dd, 4H, J= 1.83). 33: 1.73–2.50 (m, 18H, Adaman-
tyl-H, COCH3), 7.75–8.86 (m, 4H, CH, Ar-H) (Scheme 1).
3. Biological screening
3.1. Antimicrobial screening of the tested compounds
Nutrient agar plates were seeded separately with 0.1 ml of 24 h
diluted culture of S. aureus, E. coli and C. albicans. Cylindrical
plugs were removed from the agar plate using a sterile cork
borer. Five cups of 10 mm diameter were made in the seeded
agar by the aid of sterile Weatherman tube. Twenty microliter
of the solution of tested compounds in dimethylformamide
(10 mg/ml) were added into the corresponding cups in different
seeded strain agar, and 100 ll DMF were added in the ﬁfth cup
as a negative control, allowed to diffuse and incubated at 37 C
for 24 h. The zones of inhibition around each cup were mea-
sured using a caliper to the nearest 0.5 mm (Ronsted, 1972;
Blain et al., 1970).
3.2. Antiviral and cytotoxicity screening
The compound samples were prepared for assay by dissolving
in 50 ml of DMSO and diluting aliquots into sterile culture
media at 0.4 mg/ml. These solutions were subdiluted to
0.02 mg/ml in sterile media and the two solutions used as
stocks to test samples at 100, 50, 20, 10, 5, 2, and 1 lg/ml in
triplicates in the wells of microtiter plates. The compounds
were tested for antiviral activity against Herpes simplex type
1 (HSV-1) grown on Vero African green monkey kidney cells.
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Synthesis, antimicrobial and antiviral testing of some new1-adamantyl analogues 125Virus stocks were prepared as aliquots of culture medium from
Vero cells infected at multiplicity of one virion per 10 cells and
cultured 3 days. They were stored at 80 C. Working stocks
were prepared by titering virus by serial dilution in culture
medium and assayed in triplicate on Vero monolayers in the
wells of microtiter trays. Virus suspensions that gave about
30 plaques per well were stored at 4 C until used. Vero Afri-
can green monkey kidney cells were purchased from Viromed
Laboratories, Minnetonka, MN, USA and grown in Dulbec-
cos modiﬁed Eagle’s medium supplemented with 10% (v/v)
calf serum (HyClone Laboratories, Ogden, UT, USA), 60 lg/
ml Penicillin G and 100 lg/ml Streptomycin sulfate maintained
at 37 C in a humidiﬁed atmosphere containing about 15% (v/v) CO2 in air. All medium components were obtained from
Sigma Chemical Co., St. Louis, MO, USA unless otherwise
indicated. Vero stocks were maintained at 34 C in culture
ﬂasks ﬁlled with medium supplemented with 1% (v/v) calf ser-
um. Subcultures for virus titration or antiviral screening were
grown in the wells of microtiter trays (Falcon Microtest III 96-
wells trays, Becton Dickinson Labware, Lincolin Park, NJ,
USA) by suspending Vero cells in medium following trypsin–
EDTA treatment, counting the suspension with a hemocytom-
eter, diluting in medium containing 10% calf serum to 2 · 104
cells per 200 ml culture, aliquoting into each well of a tray and
culturing until conﬂuent (Hufford et al., 1991; El-Sherbeny
et al., 1995; El-Subbagh et al., 2000). Microtiter trays with con-
126 G.S. Hassan et al.ﬂuent monolayer cultures of Vero cells were inverted, the med-
ium shaken out, and replaced with serial dilutions of sterile ex-
tracts in triplicate in 100 ll medium in each well. Trays wells
were then inoculated with 30 plaque forming units of HSV-1
virus in 100 ll medium containing 10% (v/v) calf serum. In
each tray, the last row of wells was reserved for controls that
were not treated with compounds or not treated with virus.
The trays were cultured for 6 h. The trays were inverted onto
a pad of paper towels, the remaining cells rinsed carefully with
medium, and ﬁxed with 3.7% (v/v) formaldehyde in saline for
at least 20 min. The ﬁne cells were rinsed with water, and
examined visually. Antiviral activity is identiﬁed as conﬂuent,
relatively unaltered monolayers of stained Vero cells treated
with HSV-l. Cytotoxicity was estimated as the concentration
that caused approximately 50% loss of the monolayer present
around the plaques caused by HSV-l 126–128. The synthesized
compounds were tested at the University of Minnesota for
their possible antiviral and cytotoxicity activity. Aphidicolin
(0.005 lg/ml) was used as a positive control. The compounds
were tested against (HSV-1) grown on Vero African green
monkey kidney cells (Hufford et al., 1991; El-Sherbeny et al.,
1995; El-Subbagh et al., 2000).
4. Results and discussion
4.1. Chemistry
The starting material adamantane-1-carboxylic acid 1 is com-
mercially-available; it was early prepared by Nomura et al.Table 1 The melting points, yield percentages, molecular formulae
Comp. No. Ar Melting point (
4 4-FC6H4 203–205
5 4-ClC6H4 211–212
6 2-ClC6H4 262–265
7 4-BrC6H4 234–235
8 3-CH3C6H4 241–243
9 2-NO2C6H4 217–219
10 3-NO2C6H4 248–249
11 4-NO2C6H4 231–234
12 4-(Me2N)C6H4 152–156
13 2,6-Cl2C6H3 256–259
14 3,4-(CH3O)2C6H3 232–234
15 2-Cl,5-FC6H3 262–265
16 2-Cl,5-NO2C6H3 223–225
17 2-Thienyl 270–272
18 4-FC6H4 149–151
19 4-ClC6H4 182–184
20 2-ClC6H4 210–212
21 4-BrC6H4 177–179
22 3-CH3C6H4 186–188
23 4-(Me2N)C6H4 112–114
24 2,6-Cl2C6H3 195–197
25 3,4-(CH3O)2C6H3 175–177
26 2-Cl,5-FC6H3 185–187
27 2-Thienyl 230–232
28 4-FC6H4 85–89
29 2-ClC6H4 110–112
30 2-NO2C6H4 128–131
31 3-NO2C6H4 165–169
32 4-NO2C6H4 195–197
33 2-Cl,5-NO2C6H3 159–163via cyanation of 1-bromoadamantane with Cuperous cyanide
followed by hydrolysis with 60% sulphuric acid (Nomura
et al., 1994). So, methyl adamantane-1-carboxylate 2 was eas-
ily prepared following the classical esteriﬁcation method by
heating adamantane-1-carboxylic acid with pure methanol in
the presence of sulphuric acid as dehydrating agent to yield
the target ester in 98% yield. Several methods were reported
for the preparation of carboxylic acid hydrazides. These meth-
ods mainly involve the reaction of the carboxylic acid ester
(mainly the methyl or the ethyl ester) in ethanol or the acid ha-
lides with hydrazine in the presence of triethylamine (Ficarra
et al., 1983, 1984; Guzhova et al., 1986). Adamantane-1-car-
boxylic acid hydrazide 3 was successfully prepared in 95%
yield by prolonged heating of methyl adamantane-1-carboxyl-
ate with excess hydrazine hydrate for 15 h in the absence of
solvent.
The free primary amino group of carboxylic acid hydra-
zides readily reacts with carbonyl compounds to yield the cor-
responding anils (Schiff’s bases). The reaction is usually
carried out in ethanol, acetic acid or in dimethylformamide
according to the solubility of the reactants. Accordingly, ada-
mantane-1-carboxylic acid hydrazide 3 was allowed to react
with some substituted benzaldehydes, 2-thenaldehyde or 5-ni-
tro-2-thenaldehyde in ethanol for one hour to yield the corre-
sponding N-arylidene-1-adamantylcarboxhydrazides (4–17) in
85–90% yields. The reaction proceeded rapidly and the prod-
ucts were precipitated immediately during the reaction or on
cooling (Ficarra et al., 1983; Guzhova et al., 1986; Fenech
et al., 1979).of compounds 4–33.
C) Yield (%) Mol. form. (Mol. wt.)
92 C18H21FN2O (300.37)
90 C18H21ClN2O (316.82)
90 C18H21ClN2O (316.82)
95 C18H21BrN2O (361.28)
86 C19H24N2O (296.41)
89 C18H21N3O3 (327.38)
90 C18H21N3O3 (327.38)
94 C18H21N3O3 (327.38)
87 C20H27N3O (325.45)
87 C18H20Cl2N2O (351.27)
85 C20H26N2O3 (342.43)
90 C18H20ClFN2O (334.82)
85 C18H20ClN3O3 (361.82)
90 C16H20N2OS (288.41)
90 C20H23FN2O2S (374.47)
87 C20H23ClN2O2S (390.93)
85 C20H23ClN2O2S (390.93)
89 C20H23BrN2O2S (435.38)
86 C21H26N2O2S (370.51)
84 C22H29N3O2S (399.55)
85 C20H22Cl2N2O2S (425.37)
89 C22H28N2O4S (416.53)
82 C20H22ClFN2O2S (408.92)
82 C18H22N2O2S (362.51)
49 C20H23FN2O2 (342.41)
50 C20H23ClN2O2 (358.86)
39 C20H23N3O4 (369.41)
42 C20H23N3O4 (369.41)
47 C20H23N3O4 (369.41)
45 C20H22ClN3O4 (403.86)
Table 2 The inhibitory effect of the tested compounds against the gram positive bacteria Staphyloccous aureus (SA), the gram
negative bacteria Escherichia coli (EC), and the pathogenic fungi Candida albicans (CA) using 20 ll concentration of the tested
compounds. The cytotoxic concentration (CD50) and the antiviral activity against HSV-1 of the tested compounds and the antiviral
antibiotic aphidicolin.
Compound* The tested organism % Reduction in
number in plaques
Minimum Antiviral
Conc. (mg/ml)
Cytotoxicity
(CD50) mg/ml
S. aureus E. coli C. albicans
18 S++ R S++ 18 0.21 0.02
19 S+ R S+ 20 0.21 0.01
21 S++ R S+ 20 0.20 0.03
22 R R R – – –
23 S+ R R 19 0.20 0.03
24 R R R – – –
26 R R R – – –
28 S++ R S+ – – –
29 S+ R R – – –
32 R R R – – –
Ampicillin S++++ S+++ Not tested – – –
Clotrimazole Not tested Not tested S++++ – – –
Aphidicolin – – – 100 0.005 0.20
* Compounds not listed in the table are completely inactive. R = resistant, S+ = weakly active, S++ =moderately active, S+++= strongly
active, S++++= remarkably active.
Synthesis, antimicrobial and antiviral testing of some new1-adamantyl analogues 127Mercaptoacetic acid was reported to react readily with
compounds containing an arylideneamino function group in
benzene or xylene to yield the corresponding 2-aryl-4-thiazo-
lidinone derivatives (Krimmel, 1968; Moustafa et al., 1987;
El-Subbagh et al., 1990). Accordingly, some of the arylidene
derivatives 4–17 were reacted with mercaptoacetic acid in
xylene to afford the corresponding racemates (±) 3-(1-ada-
mantylcarbonylamino)-2-aryl-4-thiazolidinones (18–27). N-
Arylidenecarbox-hydrazides were reported to undergo
acetylative cyclization upon heating with acetic anhydride to
yield the corresponding 4-acetyl-5-aryl-1,3,4-oxadiazolines
(El-Gendy and Ismail, 1989). As a result, some of the arylidene
derivatives 4–17 were heated with acetic anhydride to afford
the corresponding racemates (±) 2-(1-adamantyl)-4-acetyl-5-
aryl-1,3,4-oxadiazolines (28–33) (Table 1).
4.2. Biological screening
Representative derivatives of the newly synthesized com-
pounds were tested for their antimicrobial activity against cer-
tain strains of pathogenic bacteria and the pathogenic fungi C.
albicans. In addition, their cytotoxic activity using Vero-cell
culture and their antiviral activity against Herpes Simplex
Virus type 1 (HSV-1) were also determined.
4.2.1. Antimicrobial screening
Compounds were tested for their antimicrobial activity against
the gram positive bacteria S. aureus (SA), the gram negative
bacteria E. coli (EC), and the pathogenic fungi C. albicans
(CA) using the agar diffusion method (Ronsted, 1972; Blain
et al., 1970) The broad spectrum antibiotic Ampicillin and
the antifungal drug Clotrimazole (Canasten) were used as po-
sitive controls. The zones of inhibition were measured using a
caliper to the nearest 0.5 mm. The results of the antimicrobial
screening of the tested compounds showed variable degree of
activity (Table 2). The results showed that the compounds
22, 24, 26 and 32 are devoid of any inhibitory effect against
the tested organisms. All the tested compounds except com-pounds 22, 24, 26 and 32 showed variable activity against
the gram positive bacteria S. aureus. All the tested compounds
showed variable antifungal activity against C. albicans except
compounds 22–24, 26, 29 and 32.
4.2.2. Antiviral and cytotoxicity activity
The newly synthesized compounds 18, 19, 21–24, 26, 28, 29
and 32 were tested for their cytotoxic activity using Vero-cell
culture and their antiviral activity was tested against Herpes
simplex virus type 1 (HSV-1) using the antiviral antimitotic
antibiotic aphidicolin as a positive control (Hufford et al.,
1991; El-Sherbeny et al., 1995; El-Subbagh et al., 2000). The
results of the cytotoxic and antiviral activity of the synthesized
compounds and the antiviral antibiotic Aphidicolin are shown
in (Table 2). The results showed that compounds 18, 19, 21
and 23 showed weak antiviral activity. The rest of tested com-
pounds were found to be inactive.5. Conclusion
The results of both antimicrobial and antiviral screening re-
vealed that compounds 18, 21 and 28 are the most active
agents against gram positive bacteria. Compounds 18 and 19
proved to be the most active members among the tested com-
pounds as antifungal and antiviral agents respectively.
Although compounds 19 and 21 displayed almost the same
activity as antiviral agents, the later showed higher cytotoxicity
(three times more toxic) than the former.
Structure activity correlation of the obtained results showed
that the presence of the thiazolidinone ring favors both antimi-
crobial and antiviral activities than the oxadiazoline ring. Fur-
thermore, in the thiazolidinone series, the presence of electron-
withdrawing atom at the para position of the phenyl ring fa-
vors both activities rather than electron-donating groups
which caused the loss of activity. In addition, the presence of
2,6-disubstituents of the phenyl ring resulted in loss of both
the antiviral and the antimicrobial activities.
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